The dual role of free fatty acid signaling in inflammation and therapeutics

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 3, 2013, Pages 189-197

  Volpe, Caroline M O ^a   Nogueira Machado, José A ^a  

^a Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

Free fatty acid (FFA); GPCR (G protein coupled receptors); Inflammation; PPAR (peroxisome proliferatoractivated receptors); Toll like receptors (TLR)

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; DIACYLGLYCEROL; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GAMMA LINOLENIC ACID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LONG CHAIN FATTY ACID; MEDIUM CHAIN FATTY ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPASE C; POLYUNSATURATED FATTY ACID; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SATURATED FATTY ACID; SHORT CHAIN FATTY ACID; STEARIC ACID; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL STRESS; CHEMICAL STRUCTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DOWN REGULATION; DYSLIPIDEMIA; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID METABOLISM; LIPID PEROXIDATION; LIPOTOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVERNUTRITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; DRUG THERAPY; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PATENTS AS TOPIC; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOME PROLIFERATORS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84888119031     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/18715303113139990041     Document Type: Article

References (113)

1. Andersson U, Rauvala H. Introduction: HMGB1 in inflammation and innate immunity. J Intern Med 2011; 270(4):296-300.
2. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011; 18(2):139-43.
3. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 1993; 36(4):611-22.
4. Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, Tateya S, et al. Activation of NF-kappaB by palmitate in endothelial cells: A key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol 2009; 29(9):1370-5.
5. Covington DK, Briscoe CA, Brown AJ, Jayawickreme CK. The Gprotein- coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochem Soc Trans 2006; 34(Pt 5):770-3.
6. Kim JK. Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab 2006;4(6):417-9.
7. Martins de Lima T, Gorjao R, Hatanaka E, Cury-Boaventura MF, Portioli Silva EP, Procopio J, et al. Mechanisms by which fatty acids regulate leucocyte function. Clin Sci (Lond) 2007; 113(2):65-77.
8. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116(11):3015-25.
9. Stoddart LA, Smith NJ, Milligan G. Free fatty acid receptors FFA1, -2, and -3: Pharmacology and pathophysiological functions. Pharmacol Rev 2008; 60(4):405-17.
10. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37(12):1595-607.
11. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 2012; 3:111.
12. Vinolo MA, Hirabara SM, Curi R. G-protein-coupled receptors as fat sensors. Curr Opin Clin Nutr Metab Care 2012; 15(2):112-6.
13. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9(5):367-77.
14. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89(2):463-78.
15. Bunn RC, Cockrell GE, Ou Y, Thrailkill KM, Lumpkin CK, Jr., Fowlkes JL. Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovasc Diabetol 2010; 9:73.
16. Egan BM, Lu G, Greene EL. Vascular effects of non-esterified fatty acids: Implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids 1999; 60(5-6):411-20.
17. Hennig B, Shasby DM, Spector AA. Exposure to fatty acid increases human low density lipoprotein transfer across cultured endothelial monolayers. Circ Res 1985; 57(5):776-80.
18. Horrobin DF. Abnormal membrane concentrations of 20 and 22- carbon essential fatty acids: A common link between risk factors and coronary and peripheral vascular disease? Prostaglandins Leukot Essent Fatty Acids 1995; 53(6):385-96.
19. Tsimikas S, Reaven PD. The role of dietary fatty acids in lipoprotein oxidation and atherosclerosis. Curr Opin Lipidol 1998;9(4):301-7.
20. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42(2):128-38.
21. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS- 1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103(2):253-9.
22. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A 1H NMR spectroscopy study. Diabetologia 1999; 42(1):113-6.
23. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 15; 97(12):2859-65.
24. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 200l; 106(2):171-6.
25. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11(9):351-6.
26. Koutsari C, Jensen MD. Free fatty acid metabolism in human obesity. J Lipid Res 2006; 47(8):1643-50.
27. Ajuwon KM, Spurlock ME. Palmitate activates the NF-kappaB transcription factor and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr 2005;135(8):1841-6.
28. Lambertucci RH, Hirabara SM, Silveira Ldos R, Levada-Pires AC, Curi R, Pithon-Curi TC. Palmitate increases superoxide production through mitochondrial electron transport chain and NADPH oxidase activity in skeletal muscle cells. J Cell Physiol 2008; 216(3):796-804.
29. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, et al. Differential modulation of Toll-like receptors by fatty acids: Preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003; 44(3):479-86.
30. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase- 2 mediated through Toll-like receptor 4. J Biol Chem 2001; 276(20):16683-9.
31. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: Mechanism of activation. Diabetes 2008; 57(11):3090-8.
32. Dasu MR, Jialal I. Free fatty acids in the presence of high glucose amplifies monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab 2011; 300(1):E145-54.
33. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91(2):439-46.
34. Bradley RL, Fisher FF, Maratos-Flier E. Dietary fatty acids differentially regulate production of TNF-alpha and IL-10 by murine 3T3-L1 adipocytes. Obesity (Silver Spring) 2008; 16(5):938-44.
35. Chapkin RS, Kim W, Lupton JR, McMurray DN. Dietary docosahexaenoic and eicosapentaenoic acid: Emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids 2009; 81(2- 3):187-91.
36. Duda MK, O'Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 2009; 84(1):33-41.
37. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide- 1 secretion through GPR120. Nat Med 2005;11: 90-4.
38. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent antiinflammatory and insulin-sensitizing effects. Cell 2010; 142: 687-98.
39. Dong-Soon Im. Omega-3 fatty acids in anti-inflammation (proresolution) and GPCRs Prog Lipid Res 2012; 51(3):232-7.
40. Bemis, J.E., Jirousek, M.R., Milne, J.C., Smith, J.J. Fatty acid acetylated salicylates and their uses. US8173831 (2012).
41. Bemis, J.E., Jirousek, M.R., Milne, J.C., Ting, A. Fatty acid guanidine and salicylate guanidine derivatives and their uses. US20120277305 (2012).
42. Schwartz EA, Zhang WY, Karnik SK, Borwege S, Anand VR, Laine PS, et al. Nutrient modification of the innate immune response: A novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol 2010; 30(4):802-8.
43. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1(2):135-45.
44. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168(2):554-61.
45. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: Further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93(2):578-83.
46. Lin L. RAGE on the Toll Road? Cell Mol Immunol 2006; 3(5):351-8.
47. Tobias PS, Curtiss LK. Toll-like receptors in atherosclerosis. Biochem Soc Trans 2007; 35(Pt 6):1453-5.
48. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282(48):35279-92.
49. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278(39):37041-51.
50. de Luca, C., Olefsky, J.M., Saberi, M., Verma, I.M., Woods, N.-B. Methods and compositions for ameliorating diabetes and symptoms thereof. US20100239589 (2010).
51. Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26(5):244-51.
52. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003; 92(4A):34J-41J.
53. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10(4):355-61.
54. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
55. Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc Biol Sci 1992; 247(1319):83-7.
56. Gottlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1992; 89(10):4653-7.
57. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator- activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8(3):159-66.
58. Linton MF, Fazio S. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Curr Atheroscler Re 2000; 2(1):29-35.
59. Colville-Nash PR, Qureshi SS, Willis D, Willoughby DA. Inhibition of inducible nitric oxide synthase by peroxisome proliferatoractivated receptor agonists: Correlation with induction of heme oxygenase 1. J Immunol 1998; 161(2):978-84.
60. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferatoractivated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 1999; 10(2):151-9.
61. Staels B, Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharm Des 1997; 3(1):1-14.
62. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Retardation of coronary atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther 1997; 11 (Suppl 1):257-63.
63. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96(7):2137-43.
64. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000;473(3):333-6.
65. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272(30):18779-89.
66. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79(7):1147-56.
67. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999;19(3):546-51.
68. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274(13):9116-21.
69. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11):1106-18.
70. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25(6):331-6.
71. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144(9):3765-73.
72. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105(9):1135-43.
73. Tan, B. Annatto extract compositions, including geranyl geraniols and methods of use. US8293290 (2012).
74. Ossovskaya, V.S., Sherman, B.M. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds. US7994222 (2011).
75. Jayyosi, Z., McGeehan, G.M., Kelley, M.F., Labaudiniere, R.F., Zhang, L., Groneberg, R.D., McGarry, D.G., Caufield, T.J., Minnich, A., Bobko, M. Di-aryl acid derivatives as PPAR receptor ligands. EP1177187 (2007).
76. Andrew, R., Morton, N.M., Seckl, J.R., Walker, B.R. Lipid profile modulation with steroids and PPAR alpha agonists. EP1420769 (2008).
77. Sasaki, T.A. Peroxisome proliferator-activated receptor (PPAR) activator and drug, supplement, functional food and food additive using the same. EP1829542 (2012).
78. Pettersson, I., Polivka, Z., Sauerberg, P., Sindelar, K. Phenoxyacetic acid derivatives as ppar agonists. EP1763511 (2010).
79. Bobko, M., Caulfield, T.J., Groneberg, R.D., Jayyosi, Z., Kelley, M.F., Labaudiniere, R.F., McGarry, D.G., McGeehan, G.M., Minnich, A., Morris, R., Zhang, L. Tri-aryl acid derivatives as ppar receptor ligands. EP1177176 (2002).
80. Devanaboyina, U. Methods and compositions for treating type 2 diabetes and related conditions. WO2013033432 (2013).
81. Tadakiyo, N., Kayo, M., Sen, T., Tomomi, Y., Munetaka, T., Hiroki, I., Kaori, K. Pharmaceutical composition for treating diabetes. WO2013065835 (2013).
82. Hamdouchi, C. 1,2,3,4-tetrahydroqinoline derivative useful for the treatment of diabetes. WO2013025424 (2013).
83. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21(1):90-113.
84. Wellendorph P, Johansen LD, Brauner-Osborne H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009; 76(3):453-65.
85. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278(13):11303-11.
86. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278(13):11312-9.
87. Kotarsky K, Nilsson NE, Olde B, Owman C. Improved reporter gene assays used to identify ligands acting on orphan seventransmembrane receptors. Pharmacol Toxicol 2003; 93(6):249-58.
88. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 2003; 303(4):1047-52.
89. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422(6928):173-6.
90. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1(4):245-58.
91. Graciano MF, Santos LR, Curi R, Carpinelli AR. NAD(P)H oxidase participates in the palmitate-induced superoxide production and insulin secretion by rat pancreatic islets. J Cell Physiol 2011; 226(4):1110-7.
92. Asai, N., Iwasaki, F., Kurosaki, T., Negoro, K., Ohnuki, K., Soga, T., Yonetoku, Y., Yoshida, S. Oxadiazolidinedione compound. EP2011788 (2009).
93. Bakker, R., Eckhardt, M., Hamprecht, D., Himmelsbach, F., Langkopf, E., Wagner, H. Indanyloxydihydrobenzofuranylacetic acids. US20120302566 (2012).
94. Christiansen, E., Ulven, T. Compounds for the treatment of metabolic diseases. EP2313360 (2012).
95. Clader, J.W., Davis, J.L., Greenlee, W.J., Josien, H.B., Mayer, M.J., Wan, S. Bridged and fused antidiabetic compounds. EP2389368 (2011).
96. Demarest, K., Gunnet, J., Kuo, G.H., Song, F. GPR40 agonists. US7750048 (2010).
97. Ellsworth, B.A., Ewing, W.R., Jurica, E.A. Pyrrolidine gpr40 modulators. EP2486005 (2012).
98. Xiong Y, Miyamoto N, Shibata K, Valasek MA, Motoike T, Kedzierski RM, et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci USA 2004; 101(4):1045-50.
99. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278(28):25481-9.
100. Ge H, Li X, Weiszmann J, Wang P, Baribault H, Chen JL, et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008; 149(9):4519-26.
101. Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005; 146(12):5092-9.
102. Bernard, J., Brantis, C.E., Dutheuil, G., Hoveyda, H., Schils, D., Zoute, L. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. US20110230477 (2011).
103. Hoveyda, H.R., Schils, D., Zoute, L., Parcq, J. Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43). US20130023539 (2013).
104. Wang J, Wu X, Simonavicius N, Tian H, Ling L. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem 2006; 281(45):34457-64.
105. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide- 1 secretion through GPR120. Nat Med 2005; 11(1):90-4.
106. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent antiinflammatory and insulin-sensitizing effects. Cell 2010; 142(5):687-98.
107. He, X., Zhu, X., Yang, K., Epple, R., Liu, H. Compounds and methods for modulating G protein-coupled receptors. US20130096165 (2013).
108. Shi, D.F., Song, J., Rabbat, C.J., Ma, J., Novack, A., Nashashibi, I.F., Chen, X., Pham, P. Gpr120 receptor agonists and uses thereof. US20130131351 (2013).
109. Rikitake Y, Hirata K, Yamashita T, Iwai K, Kobayashi S, Itoh H, et al. Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22(12):2049-53.
110. Vangaveti V, Shashidhar V, Jarrod G, Baune BT, Kennedy RL. Free fatty acid receptors: Emerging targets for treatment of diabetes and its complications. Ther Adv Endocrinol Metab 2010;1(4):165-75.
111. Chen J, Henderson GI, Freeman GL. Role of 4-hydroxynonenal in modification of cytochrome c oxidase in ischemia/reperfused rat heart. J Mol Cell Cardiol 2001; 33(11):1919-27.
112. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A. Free radicals, mitochondria, and oxidized lipids: The emerging role in signal transduction in vascular cells. Circ Res 2006; 99(9):924-32.
113. Musiek ES, Breeding RS, Milne GL, Zanoni G, Morrow JD, McLaughlin B. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J Neurochem 2006; 97(5):1301-13.